• Bristol Myers Squibb (NYSE:BMY) reported positive late-stage clinical trial results for two multiple myeloma candidates.
• The company announced successful Phase III data for mezigdomide in combination with Kyprolis and dexamethasone.
• Early data for its CAR T-cell therapy arlocabtagene autoleucel showed a strong response rate with a manageable safety profile.
• The results were presented at the European Hematology Association Congress 2026.

Bristol Myers Squibb is a global biopharmaceutical company focused on therapies for serious diseases, including cancer. Multiple myeloma remains an active area of research across the industry, with continued attention on both oral agents and cell therapies. These new results give investors additional detail on how NYSE:BMY is progressing in this competitive part of oncology.

For long term shareholders, the update adds context around the breadth of Bristol Myers Squibb's multiple myeloma efforts, from combination regimens to CAR T-cell approaches. The mix of late-stage and early-stage data may influence how you think about the company’s potential future product portfolio and its exposure to blood cancer treatments.

Stay updated on the most important news stories for Bristol-Myers Squibb by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Bristol-Myers Squibb.

Quick Assessment

• ✅ Price vs Analyst Target: Bristol-Myers Squibb trades at US$55.28, about 12% below the US$63.08 analyst price target.
• ✅ Simply Wall St Valuation: The stock is flagged as undervalued, trading about 54% below one fair value estimate.
• ❌ Recent Momentum: The share price is down 3.5% over the past 30 days despite the multiple myeloma trial updates.

There's only one way to know the right time to buy, sell or hold Bristol-Myers Squibb. Head to Simply Wall St's company report for the latest analysis of Bristol-Myers Squibb's Fair Value.

Key Considerations

• 📊 Positive data in multiple myeloma and early CAR T results provide more detail on how Bristol-Myers Squibb is building depth in hematology.
• 📊 It may be useful to watch how management frames timelines, regulatory plans and any follow-up studies for mezigdomide and arlocabtagene autoleucel.
• ⚠️ Analysts currently expect earnings to decline by an average of 1.8% per year over the next 3 years, so pipeline execution remains important to the longer term story.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Bristol-Myers Squibb analysis. Alternatively, you can check out the community page for Bristol-Myers Squibb to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.